¼¼°èÀÇ NAD(Nicotinamide Adenine Dinucleotide) ½ÃÀå
Nicotinamide Adenine Dinucleotide
»óǰÄÚµå : 1787235
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 276 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,206,000
PDF & Excel (Single User License) help
PDF & Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÆÄÀÏ ³» ÅØ½ºÆ®ÀÇ º¹»ç ¹× ºÙ¿©³Ö±â´Â °¡´ÉÇÏÁö¸¸, Ç¥/±×·¡ÇÁ µîÀº º¹»çÇÒ ¼ö ¾ø½À´Ï´Ù. Àμâ´Â 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,620,000
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ¹× 100% ÀÚȸ»çÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 1Àδç 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ NAD(Nicotinamide Adenine Dinucleotide) ½ÃÀåÀº 2030³â±îÁö 14¾ï ´Þ·¯¿¡ µµ´Þ

2024³â¿¡ 6¾ï 8,310¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ NAD(Nicotinamide Adenine Dinucleotide) ½ÃÀåÀº ºÐ¼® ±â°£ÀÎ 2024-2030³â¿¡ CAGR 13.3%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 14¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀÎ ½Äǰ µî±ÞÀº CAGR 14.8%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 8¾ï 3,310¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀǾàǰ µî±Þ ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ Áß CAGR 12.0%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 1¾ï 8,610¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 18.1%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ NAD(Nicotinamide Adenine Dinucleotide) ½ÃÀåÀº 2024³â¿¡´Â 1¾ï 8,610¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº ºÐ¼® ±â°£ÀÎ 2024-2030³âÀÇ CAGRÀ» 18.1%·Î, 2030³â±îÁö 3¾ï 1,080¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 9.6%¿Í 12.0%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 10.6%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°è NAD(Nicotinamide Adenine Dinucleotide) ½ÃÀå - ÁÖ¿ä µ¿Çâ ¹× ÃËÁø¿äÀÎ Á¤¸®

NAD(Nicotinamide Adenine Dinucleotide)°¡ °Ç°­ ¹× Àå¼ö ¿¬±¸¿¡¼­ ÁÖ¸ñ¹Þ´Â ÀÌÀ¯

NAD(Nicotinamide Adenine Dinucleotide)´Â ¼¼Æ÷ ´ë»ç, ¿¡³ÊÁö »ý»ê, DNA º¹±¸¿¡ ÇʼöÀûÀÎ ¿ªÇÒÀ» ÇϹǷΠ°Ç°­ ¹× À£´Ï½º »ê¾÷¿¡¼­ Áß¿äÇÑ ºÐÀÚ·Î ºÎ»óÇϰí ÀÖ½À´Ï´Ù. NAD´Â ¸ðµç »ýü ¼¼Æ÷¿¡ Á¸ÀçÇÏ´Â º¸È¿¼Ò·Î¼­ ¹ÌÅäÄܵ帮¾Æ ±â´É, »êÈ­ ½ºÆ®·¹½º ¹ÝÀÀ, ¼¼Æ÷ ³ëÈ­ °úÁ¤ÀÇ Á¶Àý¿¡ Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. °úÇÐÀû ¿¬±¸¿¡ µû¸£¸é NAD ¼öÄ¡ÀÇ °¨¼Ò´Â ³ëÈ­ ¹× ³ëÈ­ °ü·Ã Áúȯ°ú °ü·ÃÀÌ ÀÖÀ¸¸ç, ¼ö¸í ¿¬Àå ¹× ½ÅÁø´ë»ç °Ç°­ ÁõÁøÀ» À§ÇÑ NAD °­È­ º¸ÃæÁ¦, Ä¡·áÁ¦ ¹× ÀǾàǰ¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ¹ÙÀÌ¿ÀÇØÅ· Ä¿¹Â´ÏƼ, Àå¼ö ¿¬±¸ÀÚ, À£ºù ºê·£µå´Â ´ÏÄÚÆ¾¾Æ¹Ìµå¸®º¸»çÀ̵å(NR)¿Í ´ÏÄÚÆ¾¾Æ¹Ìµå ¸ð³ë´ºÅ¬·¹¿ÀƼµå(NMN)¿Í °°Àº NAD Àü±¸Ã¼ÀÇ Àα⸦ ÁÖµµÇϰí ÀÖ½À´Ï´Ù. À̵éÀº NAD »ý¼ºÀ» Áõ°¡½ÃÄÑ ¼¼Æ÷ÀÇ È¸º¹·ÂÀ» Çâ»ó½ÃŰ´Â °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖ½À´Ï´Ù. ³ëÈ­ ¹æÁö Ä¡·á, ½Å°æ º¸È£, ¸¸¼ºÁúȯ °ü¸®¿¡¼­ NAD Ä¡·áÀÇ ÅëÇÕÀº ±× ¿ëµµ¸¦ ´õ¿í È®´ëÇÏ¿© »ý¸í °øÇÐ, ¿µ¾ç º¸ÃæÁ¦, ¸ÂÃãÇü ÀÇ·á¿¡¼­ Áß¿äÇÑ °ü½É ºÐ¾ß°¡ µÇ¾ú½À´Ï´Ù. Àå¼ö Ãß±¸¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ NAD´Â Â÷¼¼´ë °Ç°­ Çõ¸íÀÇ Ãʼ®ÀÌ µÇ°í ÀÖÀ¸¸ç, Ȱ·Â, ÀÎÁö ±â´É ¹× ´ë»ç È¿À²À» °³¼±ÇÏ´Â µ¥ À¯¸Á ÀÌÁ¡À» Á¦°øÇÕ´Ï´Ù.

NAD ±â¹Ý Á¦Ç° »ó¿ëÈ­¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â °úÁ¦´Â?

NAD¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö°í ÀÖÀ½¿¡µµ ºÒ±¸Çϰí NADÀÇ »ó¾÷È­ ¹× ÇコÄÉ¾î ¹× À£´Ï½º ¿ëµµ·ÎÀÇ º¸±Þ¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ¸î °¡Áö ¹®Á¦°¡ ÀÖ½À´Ï´Ù. ÁÖ¿ä ¿ì·Á »çÇ× Áß Çϳª´Â NAD ºÎ½ºÆ® º¸ÃæÁ¦¸¦ µÑ·¯½Ñ ±ÔÁ¦ÀÇ ºÒÈ®½Ç¼ºÀ̸ç, ¼¼°è º¸°Ç±â±¸´Â ¾ÆÁ÷ º¹¿ë·®, ¾ÈÀü¼º, Àå±âÀû È¿°ú¿¡ ´ëÇÑ ¸íÈ®ÇÑ °¡À̵å¶óÀÎÀ» È®¸³ÇÏÁö ¸øÇß½À´Ï´Ù. NAD Àü±¸Ã¼, ƯÈ÷ NMN°ú NRÀº °í°¡À̱⠶§¹®¿¡ ¸¹Àº ¼ÒºñÀÚÀÇ ÀÌ¿ëÀÌ Á¦ÇÑµÇ¾î ¿µ¾ç º¸ÃæÁ¦ ½ÃÀå¿¡¼­ °¡°Ý ¼³Á¤ÀÇ À庮ÀÌ µÇ°í ÀÖ½À´Ï´Ù. °úÇÐÀû ȸÀǷеµ ¸¸¸¸Ä¡ ¾ÊÀ¸¸ç, NAD´Â ÀüÀÓ»ó½ÃÇè¿¡¼­ °¡´É¼ºÀ» º¸¿´À¸³ª, ³ëÈ­ ȸº¹°ú ¸¸¼ºÁúȯ Ä¡·á¿¡ ´ëÇÑ È¿°ú¸¦ °ËÁõÇϱâ À§Çؼ­´Â ´ë±Ô¸ð ÀÎü ½ÇÇèÀÌ ÇÊ¿äÇÕ´Ï´Ù. ¶ÇÇÑ °æ±¸¿ë NAD º¸ÃæÁ¦´Â Èí¼öÀ²ÀÌ ´Ù¸£±â ¶§¹®¿¡ Á¤¸ÆÁÖ»ç, ¼³ÇÏÁ¦Á¦, ³ª³ëÀÎĸ½¶·¹ÀÌ¼Ç ±â¼ú µî º¸´Ù È¿À²ÀûÀÎ Àü´Þ ¸ÞÄ¿´ÏÁòÀÌ ÇÊ¿äÇÕ´Ï´Ù. ½ÃÀåÀº ¶ÇÇÑ ·¹½ºº£¶óÆ®·Ñ, ÄÚ¿£ÀÚÀÓQ10, ½ºÆç¹Ìµò µî È¿´ÉÀÌ Áߺ¹µÇ´Â ´ëü Àå¼ö º¸Á¶Á¦¿ÍÀÇ °æÀï ½ÉÈ­¿¡µµ Á÷¸éÇØ ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹®Á¦¸¦ ÇØ°áÇϱâ À§Çؼ­´Â Ãß°¡ ¿¬±¸, Ç¥ÁØÈ­µÈ ÀÓ»ó °ËÁõ, À¯È¿¼º, °æÁ¦¼º, ±ÔÁ¦ Áؼö¸¦ º¸ÀåÇϱâ À§ÇÑ NAD Á¦Á¦ÀÇ ¹ßÀüÀÌ ÇÊ¿äÇÕ´Ï´Ù.

±â¼ú Çõ½ÅÀº NAD º¸ÃæÁ¦¿Í Ä¡·á¹ýÀÇ È¿°ú¸¦ ¾î¶»°Ô Çâ»ó½Ã۰í Àִ°¡?

±â¼ú ¹ßÀü°ú °úÇÐÀû ¿¬±¸´Â NAD º¸ÃæÁ¦ ¹× Ä¡·á ¿ëµµÀÇ ±â¼ú Çõ½ÅÀ» ÃËÁøÇÏ¿© Èí¼ö, È¿´É ¹× ¼ÒºñÀÚ Á¢±Ù¼ºÀ» Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. °¡Àå À¯¸Á °³¹ß Áß Çϳª´Â ¸®Æ÷Á»À̳ª ³ª³ëÀÎĸ½¶·¹ÀÌ¼ÇµÈ NAD Àü´Þ ½Ã½ºÅÛÀ» µµÀÔÇÏ¿© »ýü ÀÌ¿ë·üÀ» ³ôÀÌ°í ¼¼Æ÷ ³»·Î ´õ Àß Èí¼öµÉ ¼ö ÀÖµµ·Ï ÇÏ´Â °ÍÀÔ´Ï´Ù. Á¤¸Æ³» NAD ¿ä¹ýÀº ±â´É¼º ÀÇÇРŬ¸®´Ð¿¡¼­ Àα⸦ ¾ò°í ÀÖÀ¸¸ç, ³ëÈ­ ¹æÁö È¿°ú, ÀÎÁö ±â´É °­È­, ½ÅÁø´ë»ç ÃÖÀûÈ­¸¦ ¿øÇÏ´Â »ç¶÷µé¿¡°Ô NAD ¼öÄ¡ÀÇ ºü¸¥ ȸº¹À» Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ NAD¿Í ·¹½ºº£¶óÆ®·Ñ, ÇÁÅ׷νºÆ¿º¥, ¼­Æ©ÀΠȰ¼ºÈ­ ºÐÀÚ(STAC) µîÀÇ ½Ã³ÊÁö È­ÇÕ¹°°úÀÇ º´¿ëÀº Àå¼ö¿Í ¼¼Æ÷ º¹±¸¿¡ ´ëÇÑ È¿°ú¸¦ ³ôÀÔ´Ï´Ù. ¸ÂÃãÇü ¿µ¾çÇÐ ¹× À¯ÀüÀÚ °Ë»çÀÇ ºÎ»óµµ NAD º¸ÃæÀ» ÃÖÀûÈ­ÇÏ´Â µ¥ ÀÏÁ¶Çϰí ÀÖÀ¸¸ç, ±â¾÷Àº °³ÀÎÀÇ ´ë»ç ÇÁ·ÎÆÄÀϰú »ýȰ½À°ü ¿äÀο¡ ±â¹ÝÇÑ ¸ÂÃãÇü ÇÁ·ÎÅäÄÝÀ» Á¦°øÇÕ´Ï´Ù. ½Å°æ ÅðÇ༺ Áúȯ, ´ë»ç Àå¾Ö, ¸é¿ª °Ç°­¿¡ ´ëÇÑ NAD °­È­Á¦ÀÇ Á¦¾à ¿¬±¸´Â ±× ÀÇÇÐÀû °¡´É¼ºÀ» ´õ¿í ³ÐÇô°¡°í ÀÖ½À´Ï´Ù. ¼¼Æ÷ °Ç°­°ú ³ëÈ­¿¡ ´ëÇÑ NADÀÇ ÀÌÁ¡ÀÌ °è¼Ó ÀÔÁõµÊ¿¡ µû¶ó Á¦Çü°ú Àü´Þ ¹æ¹ýÀÇ Çõ½ÅÀº Àå¼ö ¹× À£´Ï½º ½ÃÀå¿¡¼­ »õ·Î¿î °¡´É¼ºÀ» ¿­¾îÁÙ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

NAD(Nicotinamide Adenine Dinucleotide) ½ÃÀåÀÇ ¼ºÀå ¿øµ¿·ÂÀº ¹«¾ùÀΰ¡?

NAD ½ÃÀåÀÇ ¼ºÀåÀº Àå¼ö ¹× ³ëÈ­ ¹æÁö ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ÒºñÀÚÀÇ °ü½É Áõ°¡, ´ë»ç °Ç°­¿¡ ´ëÇÑ ¿¬±¸ Áõ°¡, »ý¸í°øÇÐ ±â¼úÀÇ ¹ßÀü µî ¿©·¯ ¿äÀο¡ ÀÇÇØ ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù. ¹ÙÀÌ¿ÀÇØÅ· ¿îµ¿ÀÇ È®»ê°ú Àå¼ö¿¡ ÃÊÁ¡À» ¸ÂÃá À£ºù ÇÁ·Î±×·¥ÀÇ Àαâ·Î ÀÎÇØ NAD º¸ÃæÁ¦¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, ¼ÒºñÀÚµéÀº ¿¡³ÊÁö ´ë»ç, ÀÎÁö ±â´É, ¼¼Æ÷ ȸÃáÀ» Áö¿øÇÏ´Â Á¦Ç°À» Àû±ØÀûÀ¸·Î ã°í ÀÖ½À´Ï´Ù. ¾ËÃ÷ÇÏÀ̸Ó, ½ÉÇ÷°ü Áúȯ, 2Çü ´ç´¢º´°ú °°Àº ³ëÈ­ °ü·Ã Áúº´À» ¿¹¹æÇÒ ¼ö ÀÖ´Â °¡´É¼ºÀÌ ÀÖ´Ù°í º¸°í NAD¸¦ ÀÌ¿ëÇÑ Ä¡·á¹ýÀÌ ¿¬±¸µÇ°í Àֱ⠶§¹®ÀÔ´Ï´Ù. Á¤¹ÐÀÇ·á¿Í ¿µ¾çÀ¯ÀüüÇÐÀÌ È®´ëµÇ¸é¼­ ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õµéÀÌ NAD º¸ÃæÁ¦¸¦ °³ÀÎ ¸ÂÃãÇü °Ç°­ ÃÖÀûÈ­ °èȹ¿¡ ÅëÇÕÇÔÀ¸·Î½á ½ÃÀå ¼ºÀåÀ» ´õ¿í °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ DTC(Direct-to-Consumer) À£´Ï½º ºê·£µå¿Í E-Commerce Ç÷§ÆûÀÇ µîÀåÀ¸·Î NAD ±â¹Ý Á¦Ç°ÀÌ Àü ¼¼°è »ç¶÷µé¿¡°Ô ´õ¿í Ä£¼÷ÇÏ°Ô ´Ù°¡°¥ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©°¡ ÁøÈ­ÇÏ°í °úÇÐÀû °ËÁõÀÌ °­È­µÊ¿¡ µû¶ó NAD ½ÃÀåÀº Áö¼ÓÀûÀ¸·Î ¼ºÀåÇÏ°í °Ç°­, Àå¼ö, ´ë»ç ÃÖÀûÈ­ÀÇ ¹Ì·¡¿¡¼­ º¯ÇõÀûÀÎ ¿ªÇÒÀ» ÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ºÎ¹®

µî±Þ À¯Çü(½Äǰ µî±Þ, ÀǾàǰ µî±Þ, ±âŸ µî±Þ À¯Çü), ¿ëµµ(½ÄÀ̺¸ÃæÁ¦ ¿ëµµ, ÀǾàǰ ¿ëµµ, ¾ÈƼ¿¡ÀÌ¡ Á¦Ç° ¿ëµµ, ±âŸ ¿ëµµ)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹

AI ÅëÇÕ

Global Industry Analysts´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI Åø¿¡ ÀÇÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM³ª ¾÷°èº° SLM Äõ¸®¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ´ë·® ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÔ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Nicotinamide Adenine Dinucleotide Market to Reach US$1.4 Billion by 2030

The global market for Nicotinamide Adenine Dinucleotide estimated at US$683.1 Million in the year 2024, is expected to reach US$1.4 Billion by 2030, growing at a CAGR of 13.3% over the analysis period 2024-2030. Food Grade, one of the segments analyzed in the report, is expected to record a 14.8% CAGR and reach US$833.1 Million by the end of the analysis period. Growth in the Pharmaceutical Grade segment is estimated at 12.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$186.1 Million While China is Forecast to Grow at 18.1% CAGR

The Nicotinamide Adenine Dinucleotide market in the U.S. is estimated at US$186.1 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$310.8 Million by the year 2030 trailing a CAGR of 18.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 9.6% and 12.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 10.6% CAGR.

Global Nicotinamide Adenine Dinucleotide (NAD) Market - Key Trends & Drivers Summarized

Why Is Nicotinamide Adenine Dinucleotide (NAD) Gaining Prominence in Health and Longevity Research?

Nicotinamide adenine dinucleotide (NAD) has emerged as a critical molecule in the health and wellness industry due to its essential role in cellular metabolism, energy production, and DNA repair. As a coenzyme found in all living cells, NAD plays a key function in regulating mitochondrial function, oxidative stress response, and cellular aging processes. Scientific research has linked declining NAD levels with aging and age-related diseases, leading to increased interest in NAD-boosting supplements, therapies, and pharmaceuticals aimed at extending lifespan and enhancing metabolic health. Biohacking communities, longevity researchers, and wellness brands are driving the popularity of NAD precursors such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN), which are believed to enhance NAD production and improve cellular resilience. The integration of NAD therapies in anti-aging treatments, neuroprotection, and chronic disease management is further expanding its applications, making it a key focus area in biotechnology, nutraceuticals, and personalized medicine. As the pursuit of longevity gains momentum, NAD is becoming a cornerstone of the next-generation health revolution, offering promising benefits for improving vitality, cognitive function, and metabolic efficiency.

What Challenges Are Impacting the Commercialization of NAD-Based Products?

Despite the growing interest in NAD, several challenges impact its commercialization and widespread adoption in healthcare and wellness applications. One of the primary concerns is the regulatory uncertainty surrounding NAD-boosting supplements, as global health agencies have yet to establish clear guidelines on dosage, safety, and long-term effects. The high cost of NAD precursors, particularly NMN and NR, limits accessibility for many consumers, creating a pricing barrier in the nutraceutical market. Scientific skepticism also persists, as while NAD has demonstrated potential in preclinical studies, more extensive human trials are needed to validate its effectiveness in reversing aging or treating chronic diseases. Additionally, concerns over bioavailability pose a challenge, as oral NAD supplements have varying absorption rates, prompting the need for more efficient delivery mechanisms such as intravenous (IV) infusions, sublingual formulations, and nanoencapsulation technology. The market is also facing increasing competition from alternative longevity supplements, including resveratrol, coenzyme Q10, and spermidine, which offer overlapping benefits. Addressing these challenges will require further research, standardized clinical validation, and advancements in NAD formulation to ensure efficacy, affordability, and regulatory compliance.

How Are Innovations Enhancing the Effectiveness of NAD Supplements and Therapies?

Technological advancements and scientific research are driving innovation in NAD supplementation and therapeutic applications, improving absorption, efficacy, and consumer accessibility. One of the most promising developments is the introduction of liposomal and nanoencapsulated NAD delivery systems, which enhance bioavailability and allow for better cellular uptake. IV NAD therapy is gaining popularity in functional medicine clinics, offering rapid restoration of NAD levels for individuals seeking anti-aging benefits, cognitive enhancement, or metabolic optimization. Additionally, the combination of NAD with synergistic compounds such as resveratrol, pterostilbene, and sirtuin-activating molecules (STACs) is enhancing its effects on longevity and cellular repair. The rise of personalized nutrition and genetic testing is also playing a role in optimizing NAD supplementation, with companies offering tailored protocols based on an individual’s metabolic profile and lifestyle factors. Pharmaceutical research into NAD-boosting drugs for neurodegenerative diseases, metabolic disorders, and immune health is further expanding its medical potential. As research continues to validate the benefits of NAD in cellular health and aging, innovations in formulation and delivery methods are set to unlock new possibilities in the longevity and wellness markets.

What Is Driving the Growth of the Nicotinamide Adenine Dinucleotide (NAD) Market?

The growth in the NAD market is driven by several factors, including rising consumer interest in longevity and anti-aging solutions, increasing research into metabolic health, and advancements in biotechnology. The expanding biohacking movement and the popularity of longevity-focused wellness programs have fueled demand for NAD supplements, with consumers actively seeking products that support energy metabolism, cognitive function, and cellular rejuvenation. The aging global population is another key growth driver, as NAD-based therapies are being explored for their potential in preventing age-related diseases such as Alzheimer’s, cardiovascular disease, and type 2 diabetes. The expansion of precision medicine and nutrigenomics is further accelerating market growth, as healthcare providers integrate NAD supplementation into personalized health optimization plans. Additionally, the rise of direct-to-consumer (DTC) wellness brands and e-commerce platforms is making NAD-based products more accessible to a global audience. As regulatory frameworks evolve and scientific validation strengthens, the NAD market is expected to experience sustained growth, positioning it as a transformative player in the future of health, longevity, and metabolic optimization.

SCOPE OF STUDY:

The report analyzes the Nicotinamide Adenine Dinucleotide market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Grade Type (Food Grade, Pharmaceutical Grade, Other Grade Types); Application (Dietary Supplements Application, Pharmaceuticals Application, Anti-aging Products Application, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â